Have a feature idea you'd love to see implemented?
Let us know!
MCRB Seres Therapeutics Inc
Price (delayed)
$0.7778
Market cap
$118.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$249.54M
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to
Highlights
The EPS has shrunk by 97% QoQ but it has increased by 4.8% YoY
Seres Therapeutics's gross profit has shrunk by 100% YoY and by 100% QoQ
MCRB's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Key stats
What are the main financial stats of MCRB
Market
Valuations
Earnings
Shares outstanding
151.73M
Market cap
$118.02M
Enterprise value
$249.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
315.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
667.21
Revenue
$374,000
EBIT
-$145.95M
EBITDA
-$130.26M
Free cash flow
-$184.64M
Per share
Balance sheet
Liquidity
EPS
-$1.18
Free cash flow per share
-$1.22
Book value per share
-$0.57
Revenue per share
$0
TBVPS
$2.12
Total assets
$321.73M
Total liabilities
$408.81M
Debt
$212.63M
Equity
-$87.07M
Working capital
$40.98M
Debt to equity
-2.44
Current ratio
1.38
Quick ratio
0.92
Net debt/EBITDA
-1.01
Margins
Efficiency
Dividend
EBITDA margin
-34,827.5%
Gross margin
100%
Net margin
-43,343.6%
Operating margin
-42,211.2%
Return on assets
-46.7%
Return on equity
N/A
Return on invested capital
-43.5%
Return on capital employed
-68.4%
Return on sales
-39,025.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MCRB stock price
How has the Seres Therapeutics stock price performed over time
Intraday
0.87%
1 week
2.75%
1 month
-17.79%
1 year
-46.36%
YTD
-44.44%
QTD
-17.79%
Financial performance
How have Seres Therapeutics's revenue and profit performed over time
Revenue
$374,000
Gross profit
$374,000
Operating income
-$157.87M
Net income
-$162.11M
Gross margin
100%
Net margin
-43,343.6%
MCRB's operating income has dropped by 105% since the previous quarter and by 6% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY and by 100% QoQ
MCRB's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Seres Therapeutics's net income has plunged by 96% from the previous quarter and by 6% YoY
Growth
What is Seres Therapeutics's growth rate over time
Valuation
What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
315.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
667.21
The EPS has shrunk by 97% QoQ but it has increased by 4.8% YoY
The equity has decreased by 46% QoQ
MCRB's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Efficiency
How efficient is Seres Therapeutics business performance
The return on invested capital has dropped by 112% since the previous quarter but it has grown by 31% year-on-year
The company's return on assets has shrunk by 108% QoQ
Dividends
What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MCRB.
Financial health
How did Seres Therapeutics financials performed over time
The total assets is 21% lower than the total liabilities
The quick ratio has shrunk by 71% YoY and by 29% QoQ
MCRB's current ratio has shrunk by 57% YoY and by 18% QoQ
Seres Therapeutics's debt to equity has shrunk by 126% YoY but it has increased by 32% QoQ
The equity has decreased by 46% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.